Literature DB >> 35861904

Letter to the Editor: Lazzaro responds to Rodríguez‑Sánchez et al.

Carlo Lazzaro1,2.   

Abstract

Entities:  

Keywords:  D61; D81; H83; I1; I15; I18

Year:  2022        PMID： 35861904     DOI： 10.1007/s10198-022-01502-5

Source DB:  PubMed          Journal:  Eur J Health Econ        ISSN： 1618-7598


× No keyword cloud information.
  4 in total

Review 1.  Thinking outside the box: recent advances in the analysis and presentation of uncertainty in cost-effectiveness studies.

Authors:  Andrew H Briggs; Bernie J O'Brien; Gordon Blackhouse
Journal:  Annu Rev Public Health       Date:  2001-10-25       Impact factor: 21.981

2.  Does the inclusion of societal costs change the economic evaluations recommendations? A systematic review for multiple sclerosis disease.

Authors:  B Rodríguez-Sánchez; S Daugbjerg; L M Peña-Longobardo; J Oliva-Moreno; I Aranda-Reneo; A Cicchetti; J López-Bastida
Journal:  Eur J Health Econ       Date:  2022-05-20

3.  Economic evaluation of treating clinically isolated syndrome and subsequent multiple sclerosis with interferon beta-1b.

Authors:  Carlo Lazzaro; Cosetta Bianchi; Lucia Peracino; Paola Zacchetti; Antonio Uccelli
Journal:  Neurol Sci       Date:  2009-01-24       Impact factor: 3.307

4.  Using the net benefit regression framework to construct cost-effectiveness acceptability curves: an example using data from a trial of external loop recorders versus Holter monitoring for ambulatory monitoring of "community acquired" syncope.

Authors:  Jeffrey S Hoch; Marie Antoinette Rockx; Andrew D Krahn
Journal:  BMC Health Serv Res       Date:  2006-06-06       Impact factor: 2.655
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.